Brisbane, Oct 14, 2016 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Dr Bridges said "the R&D tax rebate is an important source of non-dilutive funding for the company and will provide an ongoing source of valuable funds for the company's R&D initiatives. The refund further strengthens Anatara's Balance Sheet".

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see for further background.



Investor inquiries:
Dr Mel Bridges
Chairman & CEO, Anatara Lifesciences
Phone: +61-413-051-600

Dr Tracey Mynott
CSO, Anatara Lifesciences
Phone: +61-405-050-113

Media inquiries:
Jane Lowe
IR department
Phone: +61-411-117-774

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 4) (Last 30 Days: 29) (Since Published: 1823) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (4639)

Research Report

Social Media